From Earlier: Merck ISENTRESS in Combination Therapy Demonstrated Long-Term Efficacy, Safety and Tolerability in Previously Untreated Adult Patients with HIV-1 for up to 240 Weeks
Merck (NYSE: MRK) yesterday announced final results from the STARTMRK study – the longest double-blind Phase III non-inferiority study evaluating an integrase inhibitor in treatment-naïve adults with HIV-1. In this pre-specified exploratory analysis of ISENTRESS® (raltegravir) 400 mg Film-coated Tablets in combination therapy in previously untreated (treatment-naïve) adult HIV-1 patients, virologic efficacy was better than the efavirenz-based regimen at 240 weeks.
At all pre-specified time points, the regimen containing ISENTRESS had fewer drug-related adverse events versus the comparator. The 240-week analysis showed that the regimen containing ISENTRESS demonstrated long-term viral suppression and a greater immunologic response, as well as a proven safety and tolerability profile.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.